Champions Oncology, Inc. (CSBR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Champions Oncology, Inc. (CSBR) is down 17.7% since the beginning of the year. At $6 per share, CSBR is trading 40.9% below its 52-week high of $10. Investors who bought $1,000 worth of CSBR shares 5 years ago would now be looking at an investment worth $590.

Champions Oncology, Inc. (CSBR) has returned -17.66% so far this year and -11.51% over the past 12 months. Over the last ten years, CSBR has returned 7.73% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Feb 2, 2007, CSBR's average daily return is +0.23%, while the average monthly return is +2.89%. At this rate, an investment would double in approximately 2.0 years.

Historically, 44% of months were positive and 56% were negative. The best month was Dec 2008 with a return of +200.0%, while the worst month was Oct 2008 at -56.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CSBR closed higher 36% of trading days. The best single day was Dec 21, 2012 with a return of +96.0%, while the worst single day was Mar 22, 2011 at -40.0%.

Champions Oncology, Inc. has an annualized alpha of 72.78%, beta of 0.41, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 05, 2007.

• This stock participated in 119.36% of S&P 500 Index downside but only 76.07% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.41 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CSBR ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Champions Oncology, Inc. (CSBR) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Champions Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Champions Oncology, Inc. was 94.13%, occurring on Sep 16, 2016. The portfolio has not yet recovered.

The current Champions Oncology, Inc. drawdown is 77.42%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Champions Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Champions Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.